CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Factsheet
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Stock Analysis
Analysis from 10-Q filed 2025-11-05. Data as of Q1 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 1.4%. FCF margin 9.7%. D/E 0.9x. Source: 10-Q filed 2025-11-05.
| Metric | Value | Context |
|---|---|---|
| ROIC | 1.4% | Below expectations |
| FCF Margin | 9.7% | Healthy cash flow |
| Debt/Equity | 0.9x | Moderate leverage |
ROIC 1.4% — Bottom 50% of sector peers. FCF margin 9.7% — Top 50%.
Explore CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: Earnings History | Filings
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for CRL: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.
Profitability: CHARLES RIVER LABORATORIES INTERNATIONAL, INC. earns 1.4% ROIC, Bottom 50% in Industrials
ROIC TTM 1.4%, sector median 7.0%, Bottom 50%. DuPont: NOPAT margin 1.9% × asset turnover 0.5x. Operating margin 1.7%. Source: 10-Q filed 2025-11-05.
| Metric | CRL | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 1.4% | Red flag | Below sector median of 7.0% |
| Return on Equity (ROE) | -5.7% | Red flag | Moderate equity returns |
| Operating Margin | 1.7% | Warning | Moderate operational efficiency |
Cash Flow: CHARLES RIVER LABORATORIES INTERNATIONAL, INC. generates $391.3M FCF at 9.7% margin, positive NaN/8 quarters
FCF TTM $391.3M. FCF margin 9.7%, Top 50%. OCF/Net income -3.3x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2025-11-05.
| Metric | CRL | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 9.7% | Adequate | Healthy cash generation |
| Free Cash Flow (TTM) | $391.3M | Good | Positive cash generation |
| OCF/Net Income | -3.3x | Warning | Potential accrual concerns |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: CHARLES RIVER LABORATORIES INTERNATIONAL, INC. at 0.9x leverage
Debt/Equity 0.9x. Total debt $2.7B, cash & investments $191.8M. Source: 10-Q filed 2025-11-05.
| Metric | CRL | Rating | Context |
|---|---|---|---|
| Debt to Equity | 0.9x | Adequate | Moderate leverage |
| Net Cash Position | $-2.5B | Warning | Net debt position |
Valuation: CHARLES RIVER LABORATORIES INTERNATIONAL, INC. trades at -43.9x earnings
P/E -43.9x. EV/Sales 2.5x. FCF yield 4.8%. Source: 10-Q filed 2025-11-05.
| Metric | CRL | Rating | Context |
|---|---|---|---|
| P/E Ratio | -43.9x | Red flag | Reasonable valuation |
| EV/Sales | 2.5x | Good | Attractive revenue multiple |
| FCF Yield | 4.8% | Good | Lower cash yield |
Capital Allocation: CHARLES RIVER LABORATORIES INTERNATIONAL, INC. returns 2.7% shareholder yield
Total shareholder yield 2.7% (buyback 2.7%). Capital returned $215.8M TTM. Source: 10-Q filed 2025-11-05.
| Metric | CRL | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 2.7% | Adequate | Dividend + buyback yield combined |
| Buyback Yield | 2.7% | Adequate | Active share repurchases |
| Total Capital Returned (TTM) | $215.8M | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 1.4% | Bottom 50% | 0.2x below |
| Free Cash Flow Margin | 9.7% | Top 50% | 2.0x above |
| Operating Margin | 1.7% | Bottom 50% | 0.2x below |
| Return on Equity (ROE) | -5.7% | Top 50% | -0.6x below |
Financial Scorecard
| Metric | CRL | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 1.4% | Red flag | Bottom 50% of sector (median: 7.0%) |
| Free Cash Flow Margin | 9.7% | Adequate | Top 50% of sector (median: 4.8%) |
| Debt to Equity Ratio | 90.8% | Adequate | Elevated but manageable |
| Free Cash Flow Yield | 4.8% | Adequate | Moderate yield |
Frequently Asked Questions
Q: What is CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s Return on Invested Capital (ROIC)?
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) has a trailing twelve-month Return on Invested Capital (ROIC) of 1.4%. Sector median 7.0%. Source: 10-Q filed 2025-11-05.
Q: What is CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s Free Cash Flow Margin?
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) has a free cash flow margin of 9.7%, generating $391.3 million in free cash flow over the trailing twelve months. Source: 10-Q filed 2025-11-05.
Q: What is CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s P/E ratio and how does it compare to peers?
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) trades at a P/E ratio of -43.9x, which is above the sector median of N/A. EV/Sales 2.5x. FCF yield 4.8%. Source: 10-Q filed 2025-11-05.
Q: How much debt does CHARLES RIVER LABORATORIES INTERNATIONAL, INC. have?
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) has a debt-to-equity ratio of 0.9x with total debt of $2.7 billion. Net debt $2.5 billion. Source: 10-Q filed 2025-11-05.
Q: What is CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s revenue and earnings growth?
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) grew revenue by 0.1% year-over-year. EPS -512.7% YoY. Source: 10-Q filed 2025-11-05.
Q: Is CHARLES RIVER LABORATORIES INTERNATIONAL, INC. buying back stock?
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) repurchased $215.8 million of stock over the trailing twelve months. This represents a buyback yield of 2.7%. Source: 10-Q filed 2025-11-05.
Q: How does CHARLES RIVER LABORATORIES INTERNATIONAL, INC. compare to competitors in Industrials?
Compared to other companies in Industrials, CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) shows: ROIC 1.4%, sector median 7.0% (Bottom 50%). FCF margin 9.7%, sector median 4.8% (Top 50%). These rankings are based on MetricDuck's analysis of all Industrials companies with available SEC filings.
Q: What warning signs should I watch for with CHARLES RIVER LABORATORIES INTERNATIONAL, INC.?
Quantitative warning flags for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL): 1) ROIC declining -7.7% over 8 quarters. Source: 10-Q filed 2025-11-05.
Data Source: Data sourced from 10-Q filed 2025-11-05. TTM metrics as of Q1 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.